A partnership agreement has been entered into by Cambridge Epigenetix (CEGX) and NuGEN Technologies to cover the manufacture and integration of technologies for epigenetic research.
Partnership
The CEGX TrueMethyl technology for oxidative bisulphite sequencing (oxBS-Seq) and NuGEN’s innovative NGS library preparation kits will be integrated as a part of this agreement. Additionally, the partnership will enable CEGX to focus on its epigenetic biomarker discovery programmes as well as further strengthening NuGEN’s epigenetics portfolio of whole genome Methyl-Seq, Reduced Representation Bisulfite Sequencing (RRBS), and patented SPET target enrichment systems.
“This partnership will enable both CEGX and NuGEN to leverage our strengths to facilitate advances in the epigenetics field. CEGX is committed to realising the promise of epigenetics through the development of improved, minimally invasive diagnostic and prognostic tests for accurate and early detection of a range of diseases, including cancer,” said Jason Mellad, CEO at Cambridge Epigenetix. “We are working with leading biopharma companies as well as progressing our own high-value internal programmes, applying our expertise and advanced proprietary technology for robust biomarker identification, particularly from liquid biopsy samples. NuGEN’s reach and reputation for delivering high-quality genomics solutions to the market makes them the ideal partner to further develop TrueMethyl technology to deliver a range of new products to enhance epigenetics research.”
“We are delighted to be working with CEGX to provide the tools to improve the understanding and appreciation of epigenetics in cellular function,” added Nitin Sood, CEO at NuGEN Technologies. “The goal of all of our products has always been to maximize the information that our customers obtain from their nucleic acid samples. By combining the TrueMethyl oxBS technology with our NGS library preparation kits, we will provide our customers with whole genome and targeted methylation products to unlock the tremendous potential of epigenetics. The combination provides access to more detailed, higher resolution epigenetic information in an integrated, cost-effective solution. The technology complements our Methyl-Seq and Single Primer Enrichment Technology product lines, and we are delighted to provide researchers with the most comprehensive solution for epigenetics research.”
Any new products formulated as a result of this partnership agreement will be available directly from NuGEN and are anticipated to be released by the end of the year.